O-7 Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
Titel:
O-7 Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
Auteur:
Kelly, R. Moehler, M. Ajani, J. Yao, J. Kuzdzal, J. Zander, T. Van Cutsem, E. Piessen, G. Mendez, G. Feliciano, J. Motoyama, S. Lièvre, A. Uronis, H. Elimova, E. Grootscholten, C. Geboes, K. Yang, Y. Zhang, J. Novosiadly, R. Cleary, J. Lei, M.